The pending $23 billion sale of Madison-based Exact Sciences to pharma giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard as a ...

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...

Q. My doctor prescribed a Cologuard test instead of a colonoscopy. No one mentioned how often Cologuard could result in false positive test results, as mine did. So, a colonoscopy was necessary after ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...

Edgewood, Ky.-based provider network St. Elizabeth Physicians has added additional drop-off locations for patients prescribed the Cologuard test. The new drop-off points are intended to improve ...

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with actor and horror icon Matthew Lillard to encourage ...

ASCs are increasingly at the forefront of colorectal cancer prevention efforts, particularly as new screening technologies gain traction. Following two FDA approvals last year, many ASCs are stepping ...